---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-234808"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-10-09T23:59:59+00:00"
generated_at: "2026-05-30T17:22:40.886623+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# UroGen Pharma appoints Christopher Degnan as CFO; Don Kim resigns effectively Oct 8, 2024

## Summary
- Don Kim resigned as CFO, principal financial and accounting officer effective Oct 8, 2024; will provide part-time consulting through Apr 28, 2025 for $36,260.
- Kim receives 9 months base salary continuation, $217,590 lump sum (2024 target bonus), and COBRA reimbursement for 9 months.
- Christopher Degnan appointed CFO effective Oct 8; prior CFO of Galera Therapeutics and Verrica Pharmaceuticals.
- Degnan receives $500,000 annual base salary, 50% target bonus, and inducement equity: option for 74,142 shares at $13.11 and 13,450 RSUs vesting over 3 years.
- Severance terms for Degnan include 6 months base salary, pro-rata bonus, and accelerated vesting of 8.33% of equity on qualifying termination.

## SEC filing metadata
- accession: 0001193125-24-234808
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-10-09T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/0001193125-24-234808-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/d838231d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-234808
- JSON: https://secwatch.observer/filing/0001193125-24-234808.json
- Plain text: https://secwatch.observer/filing/0001193125-24-234808.txt

## Key facts
- Executive change
  Don Kim resigned as Chief Financial Officer at UroGen Pharma Ltd..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: pursuant to which Mr. Kim resigned from his positions as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective October 8, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/0001193125-24-234808-index.htm
- Executive change
  Christopher Degnan was appointed as Chief Financial Officer at UroGen Pharma Ltd..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: the Company appointed Christopher Degnan as the Company’s Chief Financial Officer, principal financial officer and principal accounting officer, effective on the Effective Date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312524234808/0001193125-24-234808-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.